Activation of the stimulator of interferon genes (STING) pathway promotes antitumor
immunity but STING agonists have yet to achieve clinical success. Increased understanding …

Novel immunotherapy approaches are transforming the treatment of cancer, yet many
patients remain refractory to these agents. One hypothesis is that immunotherapy fails …

Simple Summary Immunotherapies have revolutionized the field of cancer therapeutics, yet
a substantial subset of patients fail to respond. Recent efforts have focused on identifying …

Background Activating the Stimulator of Interferon Genes (STING) adaptor incites antitumor
immunity against immunogenic tumors in mice, prompting clinical trials to test STING …

Abstract The cGAS–STING cytosolic DNA sensing pathway may play an integral role in the
initiation of antitumor immune responses. Studies evaluating the immunogenicity of various …

The advent of immunotherapy in recent years has shown the potential to revolutionize the
treatment of cancer. Unleashing antitumor T cell responses via immune checkpoint blockade …

Natural killer (NK) cells are cytotoxic innate lymphocytes that eradicate tumor cells. Inducing
durable antitumor immune responses by NK cells represents a major priority of cancer …

While STING-activating agents have shown limited efficacy in early-phase clinical trials,
multiple lines of evidence suggest the importance of tumor cell-intrinsic STING function in …

Type I interferon-mediated activation of immune cells can facilitate the generation of
productive tumor antigen-specific T cell responses in solid tumors. The cGAS/STING DNA …

Cancer immunotherapy with immune checkpoint inhibitors has achieved unprecedented
success in cancer treatment; However, only a subset of patients achieved clinical benefit …